Akt and phospholipase C are involved in the regulation of growth and migration of MDA-MB-468 breast cancer and SW480 colon cancer cells when cultured with diabetogenic levels of glucose and insulin

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Tomas, Nicola M ^a   Masur, Kai ^a,b   Piecha, Jonas C ^a   Niggemann, Bernd ^a   Zänker, Kurt S ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b Institute for Plasma Research and Technology EV INP Greifswald   (Germany)

Author keywords

Akt; Breast and colon cancer; Diabetes mellitus type 2; Glucose; Insulin; PLC

Indexed keywords

1 (6 ((3 METHOXYESTRA 1,3,5(10) TRIEN 17 YL)AMINO)HEXYL) 1H PYRROLE 2,5 DIONE; 1-(6-((3-METHOXYESTRA-1,3,5(10)-TRIEN-17-YL)AMINO)HEXYL)-1H-PYRROLE-2,5-DIONE; 2 PYRROLIDONE DERIVATIVE; ANTIDIABETIC AGENT; ENZYME INHIBITOR; ESTRANE DERIVATIVE; GLUCOSE; INSULIN; PHOSPHOLIPASE C GAMMA; PROTEIN KINASE B;

ARTICLE; BREAST TUMOR; CELL MOTION; CELL PROLIFERATION; COLON TUMOR; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ESTRENES; FEMALE; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PHOSPHOLIPASE C GAMMA; PROTO-ONCOGENE PROTEINS C-AKT; PYRROLIDINONES; UP-REGULATION;

EID: 84860371765     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-214     Document Type: Article

References (38)

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, Int J Cancer 2010 127 12 2893 2917 10.1002/ijc.25516 21351269
2. Cancer metastasis: building a framework. Gupta GP, Massague J, Cell 2006 127 4 679 695 10.1016/j.cell.2006.11.001 17110329 (Pubitemid 44781029)
3. Medical therapy for obesity: present and future. Ness-Abramof R, Nabriski D, Apovian CM, Isr Med Assoc J 2004 6 12 760 765 15609891 (Pubitemid 39646692)
4. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Rapp K, Schroeder J, Klenk J, Ulmer H, Concin H, Diem G, Oberaigner W, Weiland SK, Diabetologia 2006 49 5 945 952 10.1007/s00125-006- 0207-6 16557372
5. Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. LeRoith D, Novosyadlyy R, Gallagher EJ, Lann D, Vijayakumar A, Yakar S, Exp Clin Endocrinol Diabetes 2008 116 Suppl 1 4 S6 18777452
6. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Giovannucci E, Michaud D, Gastroenterology 2007 132 6 2208 2225 10.1053/j.gastro.2007.03.050 17498513 (Pubitemid 46693749)
7. Obesity and cancer. Pischon T, Nothlings U, Boeing H, Proc Nutr Soc 2008 67 2 128 145 10.1017/S0029665108006976 18412987 (Pubitemid 351543395)
8. Diabetes, insulin, and risk of cancer. Schiel R, Beltschikow W, Steiner T, Stein G, Methods Find Exp Clin Pharmacol 2006 28 3 169 175 10.1358/mf.2006.28.3.985230 16810343 (Pubitemid 43938540)
9. Insulin and related factors in premenopausal breast cancer risk. Del Giudice ME, Fantus IG, Ezzat S, McKeown-Eyssen G, Page D, Goodwin PJ, Breast Cancer Res Treat 1998 47 2 111 120 10.1023/A:1005831013718 9497099 (Pubitemid 28046082)
10. Increased blood glucose and insulin, body size, and incident colorectal cancer. Schoen RE, Tangen CM, Kuller LH, Burke GL, Cushman M, Tracy RP, Dobs A, Savage PJ, J Natl Cancer Inst 1999 91 13 1147 1154 10.1093/jnci/91.13.1147 10393723 (Pubitemid 29330553)
11. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, Vigneri R, Arch Physiol Biochem 2008 114 1 23 37 10.1080/13813450801969715 18465356 (Pubitemid 351998752)
12. IGF and insulin receptor signaling in breast cancer. Belfiore A, Frasca F, J Mammary Gland Biol Neoplasia 2008 13 4 381 406 10.1007/s10911-008-9099-z 19016312
13. Glycolysis as primary energy source in tumor cell chemotaxis. Beckner ME, Stracke ML, Liotta LA, Schiffmann E, J Natl Cancer Inst 1990 82 23 1836 1840 10.1093/jnci/82.23.1836 2174462
14. Insulin-like growth factors stimulate chemotaxis in human melanoma cells. Stracke ML, Kohn EC, Aznavoorian SA, Wilson LL, Salomon D, Krutzsch HC, Liotta LA, Schiffmann E, Biochem Biophys Res Commun 1988 153 3 1076 1083 10.1016/S0006-291X(88)81338-X 3291867
15. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, Testa JR, Proc Natl Acad Sci U S A 1996 93 8 3636 3641 10.1073/pnas.93.8.3636 8622988 (Pubitemid 26127592)
16. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, Ferrandina G, Benedetti Panici P, Mancuso S, Neri G, Testa JR, Int J Cancer 1995 64 4 280 285 10.1002/ijc. 2910640412 7657393
17. The protein kinase B/Akt signalling pathway in human malignancy. Nicholson KM, Anderson NG, Cell Signal 2002 14 5 381 395 10.1016/S0898-6568(01) 00271-6 11882383 (Pubitemid 34214843)
18. The activation of Akt/PKB signaling pathway and cell survival. Song G, Ouyang G, Bao S, J Cell Mol Med 2005 9 1 59 71 10.1111/j.1582-4934.2005.tb00337. x 15784165
19. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR, Greenberg ME, Science (New York, NY) 1997 275 5300 661 665 10.1126/science.275.5300.661 (Pubitemid 27061332)
20. Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Chen J, Somanath PR, Razorenova O, Chen WS, Hay N, Bornstein P, Byzova TV, Nat Med 2005 11 11 1188 1196 10.1038/nm1307 16227992 (Pubitemid 43093666)
21. Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors. Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huff JR, Huber HE, Duggan ME, Lindsley CW, Bioorg Med Chem Lett 2005 15 4 905 909 10.1016/j.bmcl.2004.12.062 15686884 (Pubitemid 40458621)
22. Physiologic implications of phosphoinositides and phospholipase C in the regulation of insulin secretion. Yamazaki H, Zawalich KC, Zawalich WS, J Nutr Sci Vitaminol 2010 56 1 1 8 10.3177/jnsv.56.1 20354339
23. Phospholipase Cgamma1 is required for metastasis development and progression. Sala G, Dituri F, Raimondi C, Previdi S, Maffucci T, Mazzoletti M, Rossi C, Iezzi M, Lattanzio R, Piantelli M, Iacobelli S, Broggini M, Falasca M, Cancer Res 2008 68 24 10187 10196 10.1158/0008-5472.CAN-08-1181 19074886
24. Elevated content of phospholipase C-gamma 1 in colorectal cancer tissues. Noh DY, Lee YH, Kim SS, Kim YI, Ryu SH, Suh PG, Park JG, Cancer 1994 73 1 36 41 10.1002/1097-0142(19940101)73:1<36::AID-CNCR2820730108>3.0.CO;2-5 8275435
25. The aminosteroid U-73122 inhibits muscarinic receptor sequestration and phosphoinositide hydrolysis in SK-N-SH neuroblastoma cells. A role for Gp in receptor compartmentation. Thompson AK, Mostafapour SP, Denlinger LC, Bleasdale JE, Fisher SK, J Biol Chem 1991 266 35 23856 23862 1660886 (Pubitemid 21908875)
26. Differential requirement of protein tyrosine kinases and protein kinase C in the regulation of T cell locomotion in three-dimensional collagen matrices. Entschladen F, Niggemann B, Zanker KS, Friedl P, J Immunol 1997 159 7 3203 3210 9317118 (Pubitemid 127482078)
27. Tumor cell locomotion: differential dynamics of spontaneous and induced migration in a 3D collagen matrix. Niggemann B, Drell TLt, Joseph J, Weidt C, Lang K, Zaenker KS, Entschladen F, Exp Cell Res 2004 298 1 178 187 10.1016/j.yexcr.2004.04.001 15242772 (Pubitemid 38887317)
28. Diabetogenic glucose and insulin concentrations modulate transcriptome and protein levels involved in tumour cell migration, adhesion and proliferation. Masur K, Vetter C, Hinz A, Tomas N, Henrich H, Niggemann B, Zanker KS, Br J Cancer 2010 104 2 345 352 21179032
29. High PKC alpha and low E-cadherin expression contribute to high migratory activity of colon carcinoma cells. Masur K, Lang K, Niggemann B, Zanker KS, Entschladen F, Mol Biol Cell 2001 12 7 1973 1982 11451996 (Pubitemid 33049692)
30. Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. Robey RB, Hay N, Semin Cancer Biol 2009 19 1 25 31 10.1016/j.semcancer.2008.11.010 19130886
31. Akt Activation is Responsible for Enhanced Migratory and Invasive Behavior of Arsenic-Transformed Human Bronchial Epithelial Cells. Wang Z, Yang J, Fisher T, Xiao H, Jiang Y, Yang C, Environ Health Perspect 2011 22766030
32. Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer. Saji M, Narahara K, McCarty SK, Vasko VV, La Perle KM, Porter K, Jarjoura D, Lu C, Cheng SY, Ringel MD, Oncogene 2011 22767330
33. Akt stimulates aerobic glycolysis in cancer cells. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB, Cancer Res 2004 64 11 3892 3899 10.1158/0008-5472.CAN-03-2904 15172999 (Pubitemid 38697301)
34. Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. Johnson SM, Gulhati P, Rampy BA, Han Y, Rychahou PG, Doan HQ, Weiss HL, Evers BM, J Am Coll Surg 2010 210 5 767 776 776-768 10.1016/j.jamcollsurg.2009.12.008 20421047
35. Insulin signalling in the heart. Bertrand L, Horman S, Beauloye C, Vanoverschelde JL, Cardiovasc Res 2008 79 2 238 248 10.1093/cvr/cvn093 18390897 (Pubitemid 351951609)
36. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Franke TF, Kaplan DR, Cantley LC, Toker A, Science (New York, NY) 1997 275 5300 665 668 10.1126/science.275.5300.665 (Pubitemid 27061333)
37. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW, Sawicki PT, Diabetologia 2009 52 9 1732 1744 10.1007/s00125-009-1418-4 19565214
38. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Baur DM, Klotsche J, Hamnvik OP, Sievers C, Pieper L, Wittchen HU, Stalla GK, Schmid RM, Kales SN, Mantzoros CS, Metabolism 2010 60 10 1363 1371 21081242